Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Revenue projections:

Revenue projections for MRNA
Revenue projections for MRNA

The projected decline in MRNA's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 2.409000
forwardPE -13.078453
debtToEquity 17.522000
earningsGrowth 0.000000
revenueGrowth 2.602000
grossMargins -0.698880
operatingMargins -1.311050
trailingEps -8.140000
forwardEps -4.155690

A current ratio of 2.409 for Moderna, Inc. implies that the company has ample liquidity to meet its short-term debts. Moderna, Inc.'s cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
MRNA's low Debt-to-Equity ratio reflects limited reliance on debt, signaling the company is not over-leveraged. This lower financial risk suggests that MRNA has a strong capital structure, which can help sustain long-term stability and attract cautious investors.

Price projections:

Price projections for MRNA
Price projections for MRNA

The price of MRNA has often been situated close to the lower end of projections. This consistent trend may signal difficulties for the company in achieving investor expectations for future performance.

Insider Transactions:

Insider Transactions for MRNA
Insider Transactions for MRNA


In recent market activity, 6 sales of MRNA shares took place, with market price at 39.020833333333336.1 separate purchases of Moderna, Inc. stock were made, while market price was at 30.270000457763672 per share.The insider transaction data shows no clear pattern or trend, making it difficult to draw any meaningful conclusions about the company's current direction based on this information.

Recommendation changes over time:

Recommendations trend for MRNA
Recommendations trend for MRNA


Analysts have shown a buy bias for MRNA, marking it as a favorable investment option. This could inspire investors to see MRNA as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.